Global Pharma News

Welcome to PharmacoLearn's Global Pharma News — your weekly briefing on the pharmaceutical developments shaping healthcare around the world. Every week we track the global pharmaceutical news that matters most to pharmacy students and professionals: FDA drug approvals, EMA decisions, breakthrough clinical trials, gene therapies, and the billion-dollar deals moving the industry. No noise, no hype — just the important global pharma updates, explained the way a pharmacist would explain them.

Week 1 — August 2026 (1–7 August 2026)

August opened with a genuine landmark. On 5 August, the US FDA approved Moderna's mFLUSIVA (mRNA-1010) for prevention of influenza A and B in adults aged 50 and older — the first influenza vaccine ever licensed in the United States on an mRNA platform. The decision rested on the Phase 3 FLUENT trial: 40,805 adults across 11 countries, showing a relative vaccine efficacy of 26.6% versus standard flu vaccines. Adults 65 and older received accelerated approval based on immunogenicity data, with a confirmatory trial required.

The backstory is as interesting as the approval itself. The FDA had initially refused to even file the application back in February 2026 over the choice of comparator — and this approval landed while US health authorities were scaling back 22 other investigational mRNA vaccine programs. So mFLUSIVA didn't just clear a scientific bar; it cleared a political one too. That context matters, because the questions pharmacists will soon face at the counter — "is this new flu shot better than the old one?" — don't have simple answers yet.

The same week delivered the largest deal in radiopharmaceutical history: Curium announced a definitive agreement to merge with Lantheus Holdings in a transaction valued at up to approximately $8.0 billion. Lantheus shareholders get $102.50 per share in cash plus contingent value rights of up to $12.00 tied to milestones through 2030. The combined company would span isotope production, diagnostics and targeted radionuclide therapy across more than 70 countries, uniting products like PYLARIFY, DEFINITY and Neuraceq with Curium's manufacturing platform.

For pharmacy students, the signal from Week 1 is clear. The mRNA platform is no longer just a COVID story — it's expanding into routine vaccinology, and pharmacists will be the ones counseling patients on what that means. And if you're watching where the industry's money and careers are flowing, radiopharmaceuticals and theranostics just had their biggest week ever.

References: AJMC — 5 August FDA approvals (https://www.ajmc.com/view/5-august-fda-approvals-marked-by-novelty-pushback); Reuters via SRN News — Curium to buy Lantheus (https://srnnews.com/curium-to-buy-lantheus-in-up-to-8-billion-deal/); GlobeNewswire — Curium/Lantheus definitive agreement (https://www.globenewswire.com/news-release/2026/08/03/3337411/0/en/curium-announces-definitive-agreement-to-merge-with-lantheus.html)

Week 2 — August 2026 (8–14 August 2026)

On 13 August, the FDA granted accelerated approval to Bristol Myers Squibb's iberdomide, marketed as Zenbexus, in combination with daratumumab, hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who had received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. The Phase 3 EXCALIBER-RRMM trial recorded a minimal residual disease-negative complete response rate of 41% versus 21% on the comparator arm. BMS describes iberdomide as the first approved cereblon E3 ligase modulator — a CELMoD — in multiple myeloma.

If that drug class sounds unfamiliar, its family tree isn't. This is the next chapter of the immunomodulatory-drug story every pharmacy student learns: thalidomide → lenalidomide → pomalidomide → now iberdomide. Each generation binds cereblon more tightly and degrades its targets — the Ikaros and Aiolos proteins driving myeloma growth — more completely. "Molecular glue degraders" have gone from a pharmacology curiosity to an approved drug class, and MRD-negativity is now the efficacy benchmark that matters.

The same day brought a quieter but significant approval: Tauklarify (florquinitau F 18), a radioactive diagnostic agent for PET imaging of the brain in adults with cognitive impairment being evaluated for Alzheimer disease, identifying tau neurofibrillary tangle pathology. As disease-modifying Alzheimer therapies — anti-amyloid and the emerging anti-tau agents — expand, PET tracers like Tauklarify become the gatekeepers deciding who actually receives treatment.

Week 2 was, in short, a week about precision: degrading exactly the right proteins in myeloma, and imaging exactly the right pathology in Alzheimer disease. Both are worth studying closely, because both point to where oncology and neuropharmacology are heading — and both will show up in your exams before you know it.

References: dpa-AFX via TradingView — New FDA Drug Approvals August 2026 (https://in.tradingview.com/news/dpa_afx:330da345ffea0:0-new-fda-drug-approvals-august-2026/); FDA — Novel Drug Approvals for 2026 (https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)

Week 3 — August 2026 (15–21 August 2026)

On 19 August, the FDA granted accelerated approval to Ultragenyx's Genglycos (pariglasgene brecaparvovec, formerly DTX401) — a one-time AAV8 liver-directed gene therapy delivering a functional G6PC gene — for adults and children aged 8 and older with glycogen storage disease type Ia, also called von Gierke disease. It is the first approved therapy targeting the underlying cause of GSDIa, indicated to reduce daily cornstarch intake as an adjunct to nutritional management. Approval rested on the Phase 3 GlucoGene study showing significant cornstarch reduction versus placebo.

Now the number that stops every conversation about this approval: the US wholesale acquisition cost is $2.7 million per patient. Genglycos is a near-perfect case study of gene-therapy economics — a single infusion replacing a lifetime of round-the-clock cornstarch feeding, granted accelerated approval with confirmatory benefit still to be verified. Whether that price is justified is exactly the kind of debate pharmacy students should be having, because payers, regulators and manufacturers will be having it for the next decade.

The same day, the FDA approved Regeneron's Pasatru (garetosmab), a fully human monoclonal antibody blocking Activin A, to reduce new heterotopic ossification lesions and flare-ups in adults with fibrodysplasia ossificans progressiva (FOP) — only the second therapy ever approved for the disease. The Phase 3 OPTIMA trial showed a 90% or greater reduction in new bone lesions at 56 weeks versus placebo. FOP affects roughly 900 people worldwide, progressively turning muscle, tendons and ligaments into bone. The application carried Breakthrough Therapy, Fast Track, Orphan Drug and Priority Review designations — the full set.

What connects these two approvals is the orphan-drug engine running at full speed: validated genetic pathways, engineered antibodies and gene vectors, and regulators willing to move fast for tiny patient populations. From a pharmacology standpoint, garetosmab's blockade of mutant ACVR1 signaling is antibody engineering at its most elegant.

References: VativoRx Pharmacy Bulletin — Genglycos approved for GSDIa (https://vativorx.com/pharmacy-bulletin-09-24-2026/); VativoRx Pharmacy Bulletin — Pasatru approved for FOP (https://vativorx.com/pharmacy-bulletin-09-17-2026/)

Week 4 — August 2026 (22–31 August 2026)

August saved its biggest oncology story for last. On 26 August, the FDA approved Revolution Medicines' daraxonrasib, marketed as Rasonque, for adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy — the first broadly applicable targeted therapy for pancreatic cancer. The Phase 3 RASolute 302 trial showed median overall survival of 13.2 months versus 6.6 months with chemotherapy (hazard ratio 0.40) and an objective response rate of 31.6%, nearly triple chemotherapy's. As a first-in-class RAS(ON) multi-selective inhibitor hitting KRAS, NRAS and HRAS across G12, G13 and Q61 mutations, it covers over 90% of pancreatic cancer patients. The FDA cleared it 6.5 months ahead of its PDUFA date, deploying Priority Review, Breakthrough Therapy, Orphan Drug status and the Commissioner's National Priority Voucher.

Read that again: survival doubled in one of the deadliest cancers known to medicine. For decades, RAS was the textbook example of an "undruggable" target — the protein every pharmacology lecture used to illustrate the limits of drug design. That era is now over. Daraxonrasib validates an entire drug class, and it rewrites what pharmacy students will learn about targeted therapy. Expect RAS(ON) inhibitors to dominate oncology conferences — and exam questions — for years.

The day before, the FDA approved Ziihera (zanidatamab), the bispecific antibody from Zymeworks licensed to Jazz Pharmaceuticals, as first-line therapy for adults with unresectable or metastatic HER2-positive gastroesophageal adenocarcinoma. Zanidatamab binds two distinct HER2 epitopes, and the approval covers use with tislelizumab plus chemotherapy for strongly HER2-positive tumors. This is the bispecific-antibody wave reaching GI cancers — and it means HER2 testing by IHC and ISH now directly determines first-line regimens in gastroesophageal cancer, just as it long has in breast cancer.

August 2026 will be remembered as an oncology-heavy month in global pharma news: an mRNA flu vaccine, a new myeloma drug class, two gene and antibody milestones for rare diseases, and finally the fall of "undruggable" RAS. If you read one month of global pharmaceutical updates this year, make it this one.

References: FDA — Oncology Approval Notifications, daraxonrasib 8/26/2026 (https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications?ra); ecancer — Dawn of RAS-targeted therapy (http://ecancer.org/en/news/28935-the-dawn-of-ras-targeted-therapy-a-landmark-breakthrough-of-daraxonrasib-in-pancreatic-cancer); dpa-AFX via TradingView — New FDA Drug Approvals August 2026 (https://in.tradingview.com/news/dpa_afx:330da345ffea0:0-new-fda-drug-approvals-august-2026/)

The September 2026 retrospective is being prepared and will appear here next.